Ruifu Pharmaceutical Technology (Guangzhou) Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ruifu Pharmaceutical Technology (Guangzhou) Co., Ltd. - overview
Established
2021
Location
Guangzhou, Guangdong, China
Primary Industry
Pharmaceuticals
About
Based in Guangzhou, China and founded in 2021, Ruifu Pharmaceutical Technology (Guangzhou) Co. , Ltd. is specializing in the research and development of innovative small molecule drugs. The company has successfully managed the entire process from R&D to market launch of a Class 1 innovative drug and has accumulated rich experience in the R&D and clinical trials of three other Class 1 innovative drugs.
In February 2026, Ruifu Pharmaceutical Technology (Guangzhou) Co. , Ltd. raised a pre-series A funding led by Xietong Investment. The company provides innovative small molecule drugs, including Class 1 innovative drugs.
Its core technology is the carbocyclic nucleoside modification (cLNA) platform, which aims to build an efficient and stable small nucleic acid drug research and development system. The company's revenue is generated by providing innovative small molecule drugs, including Class 1 innovative drugs. The company will use the funding to accelerate its project progress and team building in the field of innovative drug development.
Current Investors
Xietong Investment
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Verticals
HealthTech
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.